CIR Expert Panel Hastens Review Of Propolis Extract; Other Highlights From 164th Meeting
Cosmetic Ingredient Review’s independent expert panel finalized assessments of seven ingredients at the 6-7 March meeting, advanced two tentative safety assessments, and issued three insufficient data announcements. Propolis extract was added to the group’s 2023 priorities list while 2024 priorities remain open to public comment.
You may also be interested in...
CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request
Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.
For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.
CIR Panel’s ‘Ethereal’ Role In Cosmetics Regulation Not Clarified By MoCRA
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.